Introduction
The level of glomerular filtration rate (GFR) is accepted as the most useful index of kidney function in health and disease. Chronic kidney disease (CKD) is defined as GFR less than 60 ml/min per 1.73 m 2 as well as markers of kidney damage [1, 2] . Reduction in GFR is associated with symptoms and laboratory manifestations of kidney disease [2], as well as cardiovascular disease [3] [4] [5] , and, as has more recently been demonstrated, acute kidney injury [6 ] and medical errors [7 ] . Given the centrality of GFR to CKD diagnosis, evaluation and management, the National Kidney Education Detection Program (NKDEP) [8] in the United States and organizations in other countries recommend to laboratories to report estimated GFR (eGFR) using the Modification of Diet in Renal Disease (MDRD) study or other equation whenever a serum creatinine was ordered [9] [10] [11] . The reporting of eGFR has been received by some as a landmark in the public health campaign for the improvement in care and outcomes for patients with CKD, while others have raised concerns that the limitations of the equations lead to misclassification of patients with CKD [12] [13] [14] [15] [16] . Regardless of one's opinion, it appears as if eGFR will be an increasingly important component of clinical practice. In the United States, recent data show that greater than 77% of laboratories report eGFR [17 ] , and, by the end of 2009, the vast majority of these laboratories will use standardized creatinine assays so as to improve the accuracy of these estimates. In addition, new recommendations from NKDEP state that eGFR calculated from the MDRD study equation can be used for adjustment of medications based on kidney function [18] . In this review, we report on the recent literature (from January 2008 to September 2009) which addresses the performance of estimating equations as well as demonstration of their utility in public health and clinical practice. Our perspective is that there are both strengths and limitations of GFR estimates, and although the introduction of eGFR reporting into widespread clinical practice has been an advance, optimal interpretation and use of GFR estimates requires attention to their limitations.
A review of the literature
We first review the literature on the development and performance of estimating equations, and then review the literature describing their use in clinical practice.
Measured glomerular filtration rate and rationale for estimating equations
The gold standard measurement for GFR requires urinary or plasma clearance of exogenous markers. These measurements are difficult to perform, and GFR is usually estimated from steady-state serum levels of endogenous filtration markers. Estimating equations incorporate demographic and clinical variables as surrogates of unmeasured physiologic processes that also affect the serum level [19, 20] . Although equations are more accurate than the serum level of the marker, they only capture the average relationships between the marker and its non-GFR determinants, and the relationship between the marker and its non-GFR determinants may vary across populations and over time, as such equations may be inaccurate when applied to different populations from which they were derived [20]. 22-27,28 ,29,30 ,31 ] and Table 2 [23,30 ,31 ,32-38] describe the methods and results of the studies that have evaluated the performance of creatinine and cystatin C-based equations, respectively, from January 2008 to September 2009. Performance of estimating equations can be described according to bias, precision and accuracy, in which bias is defined as systematic deviation of eGFR compared with measured GFR using the reference ('gold') standard; imprecision is defined as random variation (or 'spread') of eGFR values centered about the measured values; and accuracy incorporates both bias and imprecision [39] . The specific metrics used for each of these parameters varied across each study. In order to compare across studies, in the tables, we provide a qualitative assessment of the equation that performs best for each of bias, precision and accuracy.
Creatinine
Eleven studies described the development or evaluation of creatinine-based equations (Table 1) [21 , 22-27,28 ,29,30 ,31 ] . Of those, six studies (55%) used standardized creatinine, which is an increase from our prior review in which 28% of the studies used appropriate creatinine methods [40] . The three creatinine equations used in these studies were the MDRD study, Cockcroft-Gault and the Mayo Clinic equations [21 , 41, 42] .
General or diverse populations
Three studies evaluated equations, in general, or diverse population samples (Table 1) . One study compared the MDRD study equation with the Mayo Clinic equation in the general population in New Zealand and showed the MDRD study equation performed better across all three measures of performance. This is inconsistent with the fact that the Mayo Clinic equation was developed in a population with and without CKD, whereas the MDRD study equation was developed in populations with CKD. Another study evaluated the Cockcroft-Gault and the MDRD study equations in 2208 Europeans and showed lesser bias with the Cockcroft-Gault equation but greater precision with the MDRD study equation [22] . In May 2009, a new equation, the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation, was developed in a pooled dataset from 10 studies that included participants of diverse clinical characteristics, with and without kidney disease, and validated in a separate dataset pooled from 16 additional studies [21 ] . In the 16 studies used for its validation, the CKD-EPI equation was more accurate than the MDRD study equation with lower bias especially at an eGFR greater than 60 ml/min per 1.73 m 2 ; however, precision was not substantially improved compared with the MDRD study equation [21 ] .
Special populations
Below, we describe the performance of creatinine-based estimating equations within special populations.
Diabetes
Three studies [23] [24] [25] evaluated the performance of the estimating equations in patients with diabetes. Overall, there does not appear to be a clear consensus that one equation is better, but most studies did not use standardized creatinine, and, therefore, optimal comparisons were not possible.
Kidney donors
One study [26] compared the performance of the Cockcroft-Gault, MDRD study and Mayo Clinic equations in 255 kidney donors. The MDRD study equation performed better than the Mayo Clinic and Cockcroft-Gault equations, consistent with the findings from the study in the general population in New Zealand described above [27] .
Asians
Matsuo et al. [28 ] modified the MDRD study equation for use in the Japanese population and standardized creatinine in 413 participants and validated in 350 participants. The modification leads to a lower GFR estimate for the same level of creatinine. The new equation led to improved performance compared with the original MDRD study equation as well as their prior modification of the MDRD study equation for use with nonstandardized creatinine methods [43] .
Another study evaluated the performance of the original MDRD study equation and the MDRD study equation modified with the Chinese and Japanese coefficients in a Chinese population [29] . In contrast to the Japanese coefficient, the Chinese coefficient leads to a higher GFR estimate for the same level of creatinine. In patients with eGFR greater than 90 ml/min per 1.73 m 2 , bias and accuracy improved with the use of the Chinese coefficient compared with the original MDRD study; however, in the GFR range of 30-59 ml/min per 1.73 m 2 , the use of the Chinese coefficient leads to worse bias and accuracy compared with the MDRD study equation.
In the Chinese population, the Japanese coefficient had greater bias across all GFR levels. This has been posited to be due to differences in GFR measurement methods, creatinine calibration or true differences in the study populations [44] .
Cystatin C Cystatin C is under investigation as a replacement for serum creatinine in estimating the GFR [34, [45] [46] [47] . Prior studies demonstrated that the combination of cystatin C and creatinine provides the best estimate [34] . A convergence of evidence now suggests that, in contrast to early reports, there are non-GFR determinants of its serum level [48, 49 ] . Nevertheless, these data also suggest that cystatin C is less dependent upon muscle mass than creatinine and should provide more accurate GFR estimates, particularly in populations with differences in muscle mass. We identified five studies that evaluated cystatin C-based equations (Table 2) [23,30 ,31 ,32,33] , two of which tested the performance in populations with decreased muscle mass.
Chronic kidney disease population
Sterner et al. [32] compared the performance of the MDRD study equation with the Grubb cystatin C-based equation [50] . The cystatin C-based equation performed superior in terms of bias, although accuracy was similar with the MDRD study equation.
Diabetes
Willems et al. [33] found that the MDRD study equation and the serum level of cystatin C were similarly accurate, whereas Rigalleau et al. [23] showed that the composite equation with both cystatin C and creatinine performed better than any of the creatinine-based equations.
Anorexia nervosa
Delanaye et al. that leads to more accurate estimates in this extremely underweight population with normal GFR. However, the greater accuracy compared with cystatin C-based equations is surprising and may suggest an independent relationship between weight and cystatin C.
Cystic fibrosis
Beringer et al. [31 ] compared the performance of cystatin-based equations with the Cockcroft-Gault and MDRD study equations in patients with cystic fibrosis. The cystatin C-based equation outperformed the other equations in terms of precision and accuracy; however, bias was not substantially different among the three equations.
Use of estimating equations
GFR-estimating equations can be used for detection, evaluation and management of kidney disease. Here, we describe the literature on their use for detection, assessment of change over time of kidney function, referral to nephrologist, drug dosage adjustment and cardiovascular disease prognosis.
Detection of chronic kidney disease
Detection of CKD is important in studies of CKD prevalence and in screening populations at increased risk to detect patients for early treatment. Numerous studies now document the high prevalence of CKD around the world. Several recent studies highlight the difficulty in detecting CKD using estimating equations.
Levey et al.
[21 ] compared the distribution of eGFR and prevalence of CKD in US adults using the MDRD study and CKD-EPI creatinine equations as applied to the National Health and Nutrition Examination Survey (NHANES) 1988-2006. As expected, owing to the lesser bias of the CKD-EPI equation compared with the MDRD study equation, the median eGFR for the population was higher (94.5 vs. 85.0 ml/min/1.73 m 2 , respectively) ( Fig. 1 ) and the overall prevalence was lower (11.5 vs. 13.1%, respectively).
Astor et al. [51 ] compared the distribution of eGFR and prevalence of CKD using the MDRD study and CKD-EPI cystatin C equations in NHANES 1988-1994 [34, 51 ] . Compared with the MDRD study equation, use of cystatin C alone or in combination with creatinine led to lower eGFR distributions and higher prevalence estimates of CKD. Foley et al. [52] compared trends over time in the distribution of eGFR using creatinine and cystatin C in NHANES 1984 NHANES -1988 NHANES and 1999 NHANES -2002 . They found a decrease in eGFR based on creatinine, as had been reported previously [53] , but not in eGFR based on cystatin C. Possible explanations for this discrepancy are differences over time in assay calibration of creatinine or cystatin C or changes over time in the distribution of non-GFR determinants of these markers.
Monitoring progression of chronic kidney disease
All currently used estimating equations have been developed from cross-sectional databases. Prior analyses of the African-American Study of Hypertension and Kidney Disease (AASK) demonstrated that eGFR leads to estimates of a slower but more precise slope of GFR decline than measured GFR. In this review period, three additional studies evaluated the performance of estimating equations to estimate changes over time in measured GFR.
In the MDRD study, there was a 28% slower mean rate of decline in eGFR compared with measured GFR, and only dietary protein affected the difference between estimated and measured GFR slope [54] . Nonetheless, differences in slope estimates were greater than 2.0 ml/min per 1.73 m 2 per year in 41% of patients owing to either differences in non-GFR determinants of serum creatinine or imprecision in measured GFR. A second study [55] [57 ,58] . The 22 additional consults per nephrologist per year translates into an increase in the rate of referral by 2.9 consults per 100 000 population, with a greater increase in women and the elderly, consistent with bias in these groups by serum creatinine. In an evaluation of eGFR reporting in Australia, monthly referrals increased by 40% following the introduction of eGFR reporting [59] . The appropriateness of nephrology referrals fell, although a greater number of patients with CKD were appropriately referred [60] . In a UK study, there was an initial increase in the number of referrals following institution of eGFR reporting, which was reversed by the introduction of a referral management program.
Use of glomerular filtration rate-estimating equations for drug dosage adjustment
In its guidance to industry, the Food and Drug Administration (FDA) states that the method for assessment of kidney function that is most widely used in clinical practice ought to be the method used for adjustment of drug dosages [61] . At the time, the Cockcroft-Gault equation was widely used, and the FDA provided this equation as an example of an estimate that could be used.
Since then, the MDRD study equation is now more widely reported, and creatinine assays are standardized to gold standard methods [17 ] .
Several studies have compared the two equations for drug dosing purposes. Table 3 lists the studies that have compared the two equations for this purpose since January 2006 [62 ,63-70] . There is substantial heterogeneity in the methods used among the studies, which complicates comparison of the two equations. First, most studies used the Cockcroft-Gault equation as the gold standard by which to compare the drug dosages. However, as the value determined from the equation is dependent upon the creatinine assay used, this is an inappropriate gold standard [18, 71] . Prior to availability of standardized creatinine assays, there was substantial variation in the creatinine assay used, which caused differences in dosing recommendations resulting from pharmacokinetic studies, even for drugs with the same pharmacokinetics. For the same medications, variation in creatinine assays among clinical laboratories caused differences in drug exposure among patients, even if drug dosing recommendations are followed. Therefore, even if the same equation used in the pharmacokinetic studies was used to assign a drug dosage, the assigned drug dosage would likely be different than intended. Only two studies compared the estimates with the gold standard of measured GFR. Second, three studies mentioned whether the creatinine method used was standardized, and, of those, only two used a standardized creatinine value. Third, five studies expressed GFR in ml/min (as appropriate for drug dosing). Finally, of the eight studies, five used actual body weight in the Cockcroft-Gault equation, whereas five used ideal body weight.
Studies also found differences in the metric used for comparison of the equations. Four studies compared concordance for drug-specific dosing levels, with concordance rates ranging from 64 to 89%. Four studies also compared the equations according to predefined CKD stages or eGFR target levels, with reported concordance rates of 37-99%. In the two studies [62 ,63] that compared eGFR with measured GFR, both showed that the MDRD study equation had greater concordance with measured GFR than the Cockcroft-Gault equation. One study [60] of inpatients receiving aminoglycoside or vancomycin compared the area under the curve for actual drug levels with the eGFR and showed greater precision for the MDRD study equation. Importantly, no study looked at adverse outcomes, side effects or ineffective doses.
Prognosis
A number of studies have shown a J-shaped relationship of GFR estimated from serum creatinine and total mortality in studies of the general population [72, 73] . This is likely due to confounding by chronic diseases associated with malnutrition and inflammation causing low creatinine generation and overestimation of measured GFR [74] . These results are especially important in evaluating the risk associated with an eGFR of less than 60 ml/min per 1.73 m 2 , as the risk in the reference group is not uniform [75] . When evaluating risk associated with an eGFR of 45-59 ml/min per 1.73 m 2 , it is more appropriate to use a more narrow reference group, such as an eGFR of 75-89 or 90-104 ml/min per 1.73 m 2 , rather than an eGFR of more than 60 ml/min per 1.73 m 2 .
Two recent studies compared the risk of an eGFR of 45-59 ml/min per 1.73 m 2 using general population studies: the Atherosclerosis Risk in Communities (ARIC) and the Australian Diabetes, Obesity and Lifestyle (AusDiab) studies using the CKD-EPI equation rather than the MDRD study equation owing to reclassification of lowrisk patients to higher eGFR when using the CKD-EPI equation [76, 77] .
Astor et al. [51 ] compared risk prediction for all-cause and cardiovascular disease mortality in NHANES 1999-1994 based on CKD-EPI cystatin C equations and the MDRD study equation. GFR estimates using cystatin C or cystatin C along with creatinine provided more accurate predictions than the MDRD study equation. In particular, the risk relationship of eGFR computed using either cystatin C or cystatin C along with creatinine with mortality was more steep at an eGFR of more than 60 ml/min per 1.73 m 2 compared with the MDRD study equation.
Conclusion
In the current era, there are advances in our understanding of the performance and utilization of GFR estimation. First, the new CKD-EPI equation developed in people with and without kidney disease, and that which uses the same four variables as the MDRD study equation, but which improves bias and risk prediction, without a decline in accuracy in people with CKD, is an important step forward. The CKD-EPI equation should replace the MDRD study equation for routine clinical use. Second, there is now recognition that there are non-GFR determinants of cystatin C, and therefore, although a better predictor of risk, is not necessarily a more accurate estimate of GFR, even in populations with low muscle mass. Indeed, the two studies that evaluated estimating equations in populations with reduced muscle mass did not clearly show cystatin C to an improvement over creatinine-based equations. New GFR estimates that are less dependent upon non-GFR determinants are required to improve GFR estimates across populations as well as within populations over time. Third, the availability of GFR reports has a substantial effect on clinical practice. However, the impact needs to be further studied, and education programs, as to how to use these estimates, need to be developed.
